搜索
Ionis Pharmaceuticals Inc
IONS添加自选
75.500USD
-2.100-2.71%
交易中 （美东）报价延迟15分钟
12.33B总市值
亏损市盈率 TTM
关于 Ionis Pharmaceuticals Inc 公司
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ionis Pharmaceuticals Inc简介
公司代码IONS
公司名称Ionis Pharmaceuticals Inc
上市日期May 17, 1991
CEOMonia (Brett P)
员工数量1069
证券类型Ordinary Share
年结日May 17
公司地址2855 Gazelle Court
城市CARLSBAD
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92010
电话17609319200
网址https://www.ionis.com/
公司代码IONS
上市日期May 17, 1991
CEOMonia (Brett P)
Ionis Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
242.66K
-5.08%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
82.66K
-60.76%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
67.50K
+1.34%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
62.21K
-16.31%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
59.86K
-9.71%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
32.68K
+0.61%
Mr. Kyle Jenne
Mr. Kyle Jenne
Executive Vice President, Chief Global Product Strategy Officer
Executive Vice President, Chief Global Product Strategy Officer
23.71K
+30.89%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
242.66K
-5.08%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
82.66K
-60.76%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
67.50K
+1.34%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
62.21K
-16.31%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
59.86K
-9.71%
收入明细
单位: USD更新时间: 2025年3月4日
单位: USD更新时间: 2025年3月4日
FY2020
FY2019
业务USD
名称
营收
占比
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
由于公司未披露，未能获取相关数据
业务
地区
业务USD
名称
营收
占比
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
股东统计
更新时间: 18 小时前
更新时间: 18 小时前
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.57%
Capital World Investors
10.87%
T. Rowe Price Investment Management, Inc.
5.51%
BlackRock Institutional Trust Company, N.A.
5.22%
Vanguard Portfolio Management, LLC
4.73%
其他
59.10%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.57%
Capital World Investors
10.87%
T. Rowe Price Investment Management, Inc.
5.51%
BlackRock Institutional Trust Company, N.A.
5.22%
Vanguard Portfolio Management, LLC
4.73%
其他
59.10%
股东类型
持股股东
占比
Investment Advisor
70.17%
Investment Advisor/Hedge Fund
19.99%
Hedge Fund
12.11%
Research Firm
1.99%
Pension Fund
1.16%
Bank and Trust
0.87%
Individual Investor
0.72%
Sovereign Wealth Fund
0.19%
Insurance Company
0.16%
机构持股
更新时间: 4月1日 周三
更新时间: 4月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2026Q1
942
197.51M
119.51%
+12.09M
2025Q4
884
176.89M
109.21%
-8.44M
2025Q3
815
172.95M
106.78%
-7.24M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
24.07M
14.57%
+383.06K
+1.62%
Dec 31, 2025
Capital World Investors
17.96M
10.87%
+5.24M
+41.17%
Dec 31, 2025
T. Rowe Price Investment Management, Inc.
9.11M
5.51%
-4.05M
-30.77%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
8.63M
5.23%
+180.41K
+2.13%
Dec 31, 2025
Wellington Management Company, LLP
6.26M
3.79%
-328.49K
-4.99%
Dec 31, 2025
Two Sigma Investments, LP
5.72M
3.46%
+2.07M
+56.76%
Dec 31, 2025
Bellevue Asset Management AG
4.80M
2.91%
-1.44M
-23.10%
Dec 31, 2025
State Street Investment Management (US)
3.97M
2.41%
-413.79K
-9.43%
Dec 31, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco Biotechnology & Genome ETF
5.24%
ARK Genomic Revolution ETF
4.11%
Virtus LifeSci Biotech Products ETF
3.34%
Franklin Genomic Advancements ETF
2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
2.57%
First Trust Health Care Alphadex Fund
2.47%
VanEck Morningstar SMID Moat ETF
2.38%
WisdomTree BioRevolution Fund
2.28%
State Street SPDR S&P Biotech ETF
2.28%
Capital Group US Small and Mid Cap ETF
2.04%
查看更多
Invesco Biotechnology & Genome ETF
占比5.24%
ARK Genomic Revolution ETF
占比4.11%
Virtus LifeSci Biotech Products ETF
占比3.34%
Franklin Genomic Advancements ETF
占比2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
占比2.57%
First Trust Health Care Alphadex Fund
占比2.47%
VanEck Morningstar SMID Moat ETF
占比2.38%
WisdomTree BioRevolution Fund
占比2.28%
State Street SPDR S&P Biotech ETF
占比2.28%
Capital Group US Small and Mid Cap ETF
占比2.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
